Literature DB >> 17073103

Multidrug-resistant Mycobacterium tuberculosis, Bangui, Central African Republic.

Laurent X Nouvel1, Eric Kassa-Kelembho, Tiago Dos Vultos, Germain Zandanga, Jean Rauzier, Carmen Lafoz, Carlos Martin, Jesus Blazquez, Antoine Talarmin, Brigitte Gicquel.   

Abstract

We investigated multidrug-resistant (MDR) Mycobacterium tuberculosis strains in Bangui, Central African Republic. We found 39.6% with the same spoligotype and synonymous single nucleotide polymorphism in the mutT1 gene. However, strains had different rpoB mutations responsible for rifampin resistance. MDR strains in Bangui may emerge preferentially from a single, MDR-prone family.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17073103      PMCID: PMC3298286          DOI: 10.3201/eid1209.060361

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Tuberculosis (TB) is a major public health problem and causes 2 million deaths each year. Ninety-five percent of cases are in developing countries, where limited healthcare resources lead to incomplete case and contact tracing, inadequate treatment, and as a consequence, to a larger drug resistance problem (,). Multidrug-resistant TB (MDRTB), defined as resistant to at least rifampin and isoniazid, is more difficult to treat and can cost 100× more than susceptible TB; it is associated with a high death rate in HIV-infected patients (,). MDRTB results from the selection of MDR strains in patients who failed to complete chemotherapy with the correct combination of drugs. The typing of MDR strains can be used to describe transmission and outbreaks, as shown by the identification of MDR epidemics due to the Beijing/W family strains (). Other types, including Haarlem and Mycobacterium bovis isolates, have been involved in MDR outbreaks (,). Because MDR strains carry mutations in major metabolic pathways, some researchers have suggested that they may be less virulent and less transmissible (); however, the occurrence of epidemics involving these strains would seem to contradict this suggestion. As with other MDR bacterial species, they may have emerged from strains more adapted to the local population (). We have previously described variations in putative anti-mutator genes in Beijing/W isolates that may have favored adaptive mutations in this family of strains. The failure to show mutator phenotypes in Beijing/W strains suggests that this role may have been transient (,). We studied MDRTB strains in Bangui, Central African Republic (CAR), because little information has been collected concerning MDRTB in sub-Saharan Africa. In CAR, the incidence of TB is estimated to be 250 per 100,000 inhabitants, and 1.1% of cases are MDR (). In Bangui, ≈15% of the sexually active population is infected with HIV. We spoligotyped MDR strains collected by the Pasteur Institute of Bangui and looked for diversity in a series of putative anti-mutator genes.

The Study

We studied 53 MDR M. tuberculosis strains isolated from different patients between 1993 and 2001 at the Bangui Pasteur Institute. Fourteen of these patients were HIV positive, 30 were HIV negative, and 9 were of undetermined status. Epidemiologic enquiries did not show a social link among patients (unpub. data). A non-MDR, nonbiased control group, which included 263 M. tuberculosis and 2 M. bovis strains, was also studied. These strains included all those from the cohort studied by Espinal et al. () for which a subculture was obtained. All 318 isolates were typed by using the spoligotyping method previously described (). Spoligotypes were obtained for 283 (53 MDR and 230 non-MDR strains) of the 318 isolates and were analyzed with BioNumerics software (Applied Maths, Kortrijk, Belgium). Dendrograms were constructed according to degree of similarity (Dice coefficient) and comparison with known spoligotypes. Seventy-nine different spoligotypes were identified: 55 included only a single strain, and 24 included 2–56 strains. The 24 clusters were named A to X (Figure A1).
Figure A1

Dendrogram of patterns of the 283 strains spoligotyped (53 multidrug-resistant [MDR] and 230 non-MDR strains). For a printer friendly version of Figure A1, available at http://wwwnc.cdc.gov/eid/pdfs/06-0361-FA1.pdf.

The 53 MDR strains clustered in 8 clusters (Figure, panel A). Twenty-five (47.2%) of 53 clustered in type E, which has characteristics of the T family (ancient M. tuberculosis strains with numerous spacers [14]). The 230 spoligotype patterns of non-MDR strains were grouped into 22 clusters, and spoligotype E was not a major cluster (Figure, panel B). Cluster Q contained the largest number of strains. Its spoligotype is identical to the DB3 pattern ST47 characteristic of the Haarlem family (). Spoligotypes 97%–99% identical with profiles characteristic of the Haarlem family of strains represent 155 strains. These observations confirm the predominance of the Haarlem type in Africa. However, the Haarlem family was not predominant in our collection of MDR isolates.
Figure

Strain distribution into various clusters observed among 53 spoligotyped multidrug-resistant (MDR) strains (A) and 230 spoligotyped non-MDR strains (B).

Strain distribution into various clusters observed among 53 spoligotyped multidrug-resistant (MDR) strains (A) and 230 spoligotyped non-MDR strains (B). The clustering of MDR strains suggested an MDR outbreak; therefore, we looked for other characteristics in cluster E isolates. First, we tested for diversity in the rpoB region, which was likely to be responsible for rifampin resistance. Five variants were found among the 26 MDR strains that constituted clusters E and F (Table): 9 had a Ser-531 (TCG) to Leu (TTG) substitution; 8 and 5 strains contained a substitution of His-526 (CAC) with Tyr (TAC) and Arg (CGC), respectively; 3 had an Asp-516 (GAC) to Val (GTC) variant; and 1 a Leu-533 (CTG) to Pro (CCG) substitution. All these variations are in the rifampin resistance-determining region frequently encountered in strains with a rifampin-resistant phenotype (). These variants probably determine rifampin resistance and may have occurred independently, not necessarily corresponding to MDRTB transmission, even for strains of the same cluster with the same change in rpoB. Indeed, sociodemographic and epidemiologic characterization of the patients did not show any links between these MDRTB cases. Therefore, rifampin resistance seems to have been acquired independently and repeatedly by cluster E and F strains. To find a way to reduce the dissemination of such strains likely to generate MDR isolates, we characterized strains of cluster E and F. In particular, we looked for single nucleotide polymorphisms (SNPs) in the putative genes mutT1, mutT2, mutT3, Rv3908, mutY, mutM, ada/alkA, and ogt. Sequencing was performed as previously described (). With reference to published M. tuberculosis sequences, we found 1 synonymous SNP in mutT1 corresponding to Val 265 (GTC) to Val (GTA). This SNP is only present in strains of cluster E and strains 27 (cluster F), 28, and 29 and is absent from all strains in other clusters. Therefore, these MDR strains are characterized by a spoligotype pattern (ST 52 ± spacer 11 or 12 to 15 and ST 107) and the presence of the mutT1 SNP 265.
Table

rpoB mutations observed in strains of cluster E and F*

ClusterNo.ATB rpoB mutT1
E7R/I/EAsp GAC 516 Val GTCVal GTC 265 Val GTA
E8R/I/SAsp GAC 516 Val GTCVal GTC 265 Val GTA
E9R/I/E/SAsp GAC 516 Val GTCVal GTC 265 Val GTA
E10R/I/SHis CAC 526 Arg CGCVal GTC 265 Val GTA
E11R/I/E/SHis CAC 526 Arg CGCVal GTC 265 Val GTA
E45R/I/E/SHis CAC 526 Arg CGCVal GTC 265 Val GTA
E46R/I/E/SHis CAC 526 Arg CGCND
E12R/I/E/SHis CAC 526 Asp GACVal GTC 265 Val GTA
E13R/I/EHis CAC 526 Tyr TACVal GTC 265 Val GTA
E14R/I/E/SHis CAC 526 Tyr TACVal GTC 265 Val GTA
E15R/I/EHis CAC 526 Tyr TACVal GTC 265 Val GTA
E16R/I/SHis CAC 526 Tyr TACVal GTC 265 Val GTA
E17R/I/E/SHis CAC 526 Tyr TACVal GTC 265 Val GTA
E18R/IHis CAC 526 Tyr TACVal GTC 265 Val GTA
E19R/I/EHis CAC 526 Tyr TACVal GTC 265 Val GTA
E47R/I/E/SHis CAC 526 Tyr TACND
E20R/I/ESer TCG 531 Leu TTGVal GTC 265 Val GTA
E21R/I/E/SSer TCG 531 Leu TTGVal GTC 265 Val GTA
E22R/I/E/SSer TCG 531 Leu TTGVal GTC 265 Val GTA
E23R/I/E/SSer TCG 531 Leu TTGVal GTC 265 Val GTA
E24R/I/ESer TCG 531 Leu TTGVal GTC 265 Val GTA
E44R/I/E/SSer TCG 531 Leu TTGVal GTC 265 Val GTA
F27R/I/SSer TCG 531 Leu TTGVal GTC 265 Val GTA
E49R/I/E/SSer TCG 531 Leu TTGVal GTC 265 Val GTA
E50R/I/E/SSer TCG 531 Leu TTGND
E48R/ILeu CTG 533 Pro CCGND

*ATB, antibiogram results, indicates strains resistant to rifampin (R), isoniazid (I), ethambutol (E), and streptomycin (S); ND, not determined.

*ATB, antibiogram results, indicates strains resistant to rifampin (R), isoniazid (I), ethambutol (E), and streptomycin (S); ND, not determined. MDR strains of clusters E and F and strains 28 and 29 (a single difference in spacers between E and F, strain 28 or 29) corresponded to 9 new cases and 19 patients who had received previous treatment. MDR strains in other clusters corresponded to 9 new cases, 15 previously treated patients, and 1 case for which no history was available ().

Conclusions

We used 2 types of markers to study the genetic diversity of MDR M. tuberculosis strains isolated in Bangui: spoligotyping and SNPs in a series of putative DNA repair genes. Many MDR strains were clustered in 1 spoligotype and carried the same SNP in the anti-mutator gene mutT1. Indeed, 25 of the 53 MDR strains were in cluster E. Thirty-two percent of these MDR strains were from new cases of infection, and 40% were from HIV-infected patients. This cluster was not a major cluster among the 265 non-MDR isolates collected during a 5-month period. The same SNP was found in all strains of cluster E and F tested and in 2 strains that differed by 1 spacer. These strains carry variants of rpoB that confer rifampin resistance, which implies that these strains do not correspond to an MDR-TB outbreak. However, this finding is consistent with the possibility that these strains represent an MDR-prone family, members of which are often associated with MDR phenotypes in Bangui. Detection of strains characterized by the T family spoligotype and mutT1 SNP 265 may be useful to identify patients at risk of developing MDR-TB.
  15 in total

Review 1.  Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update.

Authors:  S Ramaswamy; J M Musser
Journal:  Tuber Lung Dis       Date:  1998

2.  Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.

Authors:  M A Espinal; A Laszlo; L Simonsen; F Boulahbal; S J Kim; A Reniero; S Hoffner; H L Rieder; N Binkin; C Dye; R Williams; M C Raviglione
Journal:  N Engl J Med       Date:  2001-04-26       Impact factor: 91.245

3.  Drug-susceptible Mycobacterium tuberculosis Beijing genotype does not develop mutation-conferred resistance to rifampin at an elevated rate.

Authors:  Jim Werngren; Sven E Hoffner
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

Review 4.  The burden of drug-resistant tuberculosis and mechanisms for its control.

Authors:  M C Raviglione; R Gupta; C M Dye; M A Espinal
Journal:  Ann N Y Acad Sci       Date:  2001-12       Impact factor: 5.691

5.  High rate of tuberculosis reinfection during a nosocomial outbreak of multidrug-resistant tuberculosis caused by Mycobacterium bovis strain B.

Authors:  A Rivero; M Márquez; J Santos; A Pinedo; M A Sánchez; A Esteve; S Samper; C Martín
Journal:  Clin Infect Dis       Date:  2000-12-11       Impact factor: 9.079

6.  Determinants of drug-resistant tuberculosis: analysis of 11 countries.

Authors:  M A Espinal; K Laserson; M Camacho; Z Fusheng; S J Kim; R E Tlali; I Smith; P Suarez; M L Antunes; A G George; N Martin-Casabona; P Simelane; K Weyer; N Binkin; M C Raviglione
Journal:  Int J Tuberc Lung Dis       Date:  2001-10       Impact factor: 2.373

7.  Mycobacterium tuberculosis Beijing genotype strains associated with febrile response to treatment.

Authors:  R van Crevel; R H Nelwan; W de Lenne; Y Veeraragu; A G van der Zanden; Z Amin; J W van der Meer; D van Soolingen
Journal:  Emerg Infect Dis       Date:  2001 Sep-Oct       Impact factor: 6.883

8.  Global distribution of Mycobacterium tuberculosis spoligotypes.

Authors:  Ingrid Filliol; Jeffrey R Driscoll; Dick Van Soolingen; Barry N Kreiswirth; Kristin Kremer; Georges Valétudie; Dang Duc Anh; Rachael Barlow; Dilip Banerjee; Pablo J Bifani; Karine Brudey; Angel Cataldi; Robert C Cooksey; Debby V Cousins; Jeremy W Dale; Odir A Dellagostin; Francis Drobniewski; Guido Engelmann; Séverine Ferdinand; Deborah Gascoyne-Binzi; Max Gordon; M Cristina Gutierrez; Walter H Haas; Herre Heersma; Gunilla Källenius; Eric Kassa-Kelembho; Tuija Koivula; Ho Minh Ly; Athanasios Makristathis; Caterina Mammina; Gerald Martin; Peter Moström; Igor Mokrousov; Valérie Narbonne; Olga Narvskaya; Antonino Nastasi; Sara Ngo Niobe-Eyangoh; Jean W Pape; Voahangy Rasolofo-Razanamparany; Malin Ridell; M Lucia Rossetti; Fritz Stauffer; Philip N Suffys; Howard Takiff; Jeanne Texier-Maugein; Véronique Vincent; Jacobus H De Waard; Christophe Sola; Nalin Rastogi
Journal:  Emerg Infect Dis       Date:  2002-11       Impact factor: 6.883

9.  Tuberculosis due to resistant Haarlem strain, Tunisia.

Authors:  Helmi Mardassi; Amine Namouchi; Raja Haltiti; Mourad Zarrouk; Besma Mhenni; Anis Karboul; Neila Khabouchi; Nico C Gey van Pittius; Elizabeth M Streicher; Jean Rauzier; Brigette Gicquel; Koussay Dellagi
Journal:  Emerg Infect Dis       Date:  2005-06       Impact factor: 6.883

10.  Spoligotype database of Mycobacterium tuberculosis: biogeographic distribution of shared types and epidemiologic and phylogenetic perspectives.

Authors:  C Sola; I Filliol; M C Gutierrez; I Mokrousov; V Vincent; N Rastogi
Journal:  Emerg Infect Dis       Date:  2001 May-Jun       Impact factor: 6.883

View more
  6 in total

Review 1.  TB and HIV in the Central African region: current knowledge and knowledge gaps.

Authors:  S Janssen; M A M Huson; S Bélard; S Stolp; N Kapata; M Bates; M van Vugt; M P Grobusch
Journal:  Infection       Date:  2013-12-06       Impact factor: 3.553

2.  Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol.

Authors:  Shashikant Srivastava; Sandirai Musuka; Carleton Sherman; Claudia Meek; Richard Leff; Tawanda Gumbo
Journal:  J Infect Dis       Date:  2010-04-15       Impact factor: 5.226

3.  Genomic Insight into Mechanisms of Reversion of Antibiotic Resistance in Multidrug Resistant Mycobacterium tuberculosis Induced by a Nanomolecular Iodine-Containing Complex FS-1.

Authors:  Aleksandr I Ilin; Murat E Kulmanov; Ilya S Korotetskiy; Rinat A Islamov; Gulshara K Akhmetova; Marina V Lankina; Oleg N Reva
Journal:  Front Cell Infect Microbiol       Date:  2017-05-08       Impact factor: 5.293

4.  Molecular epidemiology of drug resistant Mycobacterium tuberculosis in Africa: a systematic review.

Authors:  Namaunga Kasumu Chisompola; Elizabeth Maria Streicher; Chishala Miriam Kapambwe Muchemwa; Robin Mark Warren; Samantha Leigh Sampson
Journal:  BMC Infect Dis       Date:  2020-05-13       Impact factor: 3.090

5.  A non-sense mutation in the putative anti-mutator gene ada/alkA of Mycobacterium tuberculosis and M. bovis isolates suggests convergent evolution.

Authors:  Laurent X Nouvel; Tiago Dos Vultos; Eric Kassa-Kelembho; Jean Rauzier; Brigitte Gicquel
Journal:  BMC Microbiol       Date:  2007-05-16       Impact factor: 3.605

6.  Whole genome sequencing data of 1110 Mycobacterium tuberculosis isolates identifies insertions and deletions associated with drug resistance.

Authors:  Xi Zeng; Jamie Sui-Lam Kwok; Kevin Yi Yang; Kenneth Siu-Sing Leung; Mai Shi; Zhiyuan Yang; Wing-Cheong Yam; Stephen Kwok-Wing Tsui
Journal:  BMC Genomics       Date:  2018-05-16       Impact factor: 3.969

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.